Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to HIV virological suppression

HIV Medicine 2026 Open access

Read full text
Authors: Teresa Aldámiz‐Echevarría, Francisco Tejerina, Chiara Fanciulli, Cristina Diez, Leire Pérez, José María Bellón, Núria Espinosa, Santiago Moreno Guillen, María del Mar Arcos-Rueda, Marta Montero‐Alonso, Lucio García-Fraile, V Asensi
+18 more Marian Fernandez Lopez, Diana Corona-Mata, Alfonso Cabello-Úbeda, Meritxell Gavalda Manso, JA Iribarren, Laura Pérez‐Martínez, María Remedios Alemán Valls, Irene Portilla‐Tamarit, Joaquim Peraire, Ines Suarez-García, Mar Masiá, María José Núñez Orantos, Ángela Gutiérrez Liarte, Arkaitz Imaz, Cristina Hernández Gutiérrez, María Tasias Pitarch, Marta Rava, CoRIS Cohort
DOI: 10.1111/hiv.70257
Cited by: 1
References: 27

Abstract

OBJECTIVES: Lymphomas remain among the most frequent HIV-associated malignancies, with risk persisting despite effective virological control. This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non-Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma-related mortality at 1 year and overall survival at 5 years. METHODS: We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV-1 RNA

Fields of Study & Subjects

Viral-associated cancers and disorders Lymphoma Diagnosis and Treatment HIV Research and Treatment

Publication details

Journal / source
HIV Medicine
Publisher
Wiley
Volume
27
Issue
8
Pages
1312–1332
Publication date
17 May 2026
Language
EN